Fig. 2.
Treatment with the NPC1L1 inhibitor EZE does not unmask a role for intestinal SR-BI in cholesterol absorption. Male WT and SR-BIhApoCIII-ApoAIV-Tg (SR-BI) littermates were fed a diet containing 0.015% cholesterol (w/w) for 4 weeks. After 4 weeks on diet, mice were orally gavaged daily for 3 consecutive days with either vehicle (VEH) or 0.3 mg EZE. A: Fractional cholesterol absorption measured by fecal dual-isotope method for feces collected during the first 48 h of the experiment. B, C: Mass fecal neutral sterol loss (FNSL) determined by gas-liquid chromatography measured after 4 weeks on diet prior to EZE treatment at baseline (B), 1 day (C), or 2 days (D) post-EZE treatment. Data represent the mean ± SEM from 6 to 10 mice per group, and values not sharing the same superscript differ significantly (P < 0.05).